Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Laparoscopic Interval Debulking Surgery

Research Leaders

5 sponsors active, led by Aivita Biomedical, Inc.

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT02033616Phase 2Unknown

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas

NCT02324595Phase 2CompletedPrimary

Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study

Showing all 2 trials

Research Network

Common Treatments

  • Laparoscopic Interval Debulking Surgery1
  • Avova11
  • Mc1

Active Sponsors

  • Aivita Biomedical, Inc.1
  • Catholic University of the Sacred Heart1
  • Fagotti, Anna, M.D.1
  • Fanfani, Francesco, M.D.1
  • Salvatore Gueli Alletti1

Top Investigators

Related Conditions

  • Effects Of Chemotherapy1
  • Fallopian Tube Carcinoma1
  • Primary Peritoneal Carcinoma1
  • Stage Iii Ovarian Carcinoma1
  • Peritoneal Cavity Cancer1

Activity Timeline